Nit-Occlud Pda
Payments companies reported to CMS as associated with Nit-Occlud Pda. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Nit-Occlud Pda, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Nit-Occlud Pda
These are the largest totals companies reported as associated with Nit-Occlud Pda. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Thomas Forbes | Detroit, MI | Pediatric Cardiology | $46,039.54 |
| Gareth Morgan | Aurora, CO | Interventional Cardiology | $29,583.63 |
| Darren Berman | Los Angeles, CA | Cardiovascular Disease | $15,863.12 |
| Daniel Levi | Los Angeles, CA | Pediatric Cardiology | $14,329.74 |
| Jenny Zablah Alabi | Aurora, CO | Interventional Cardiology | $12,254.61 |
| Juan Samayoa Escobar | Minneapolis, MN | Pediatric Cardiology | $11,153.91 |
| Ada Stefanescu | Boston, MA | Interventional Cardiology | $6,344.77 |
| Jeffrey Delaney | Durham, NC | Pediatric Cardiology | $6,054.02 |
| Gurumurthy Hiremath Mallikarjun | Minneapolis, MN | Pediatrics | $5,107.68 |
| Dominic Zanaboni | Saint Louis, MO | Pediatric Cardiology | $2,948.34 |
Prescribed Nit-Occlud Pda?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.